VivoSim Labs (VIVS) Competitors $4.15 +0.22 (+5.60%) As of 09/19/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsSEC FilingsShort InterestTrendsBuy This Stock VIVS vs. LVTX, ATHE, XLO, JSPR, PLUR, PYRGF, SNTI, XFOR, DYAI, and MURAShould you be buying VivoSim Labs stock or one of its competitors? The main competitors of VivoSim Labs include LAVA Therapeutics (LVTX), Alterity Therapeutics (ATHE), Xilio Therapeutics (XLO), Jasper Therapeutics (JSPR), Pluri (PLUR), PyroGenesis Canada (PYRGF), Senti Biosciences (SNTI), X4 Pharmaceuticals (XFOR), Dyadic International (DYAI), and Mural Oncology (MURA). These companies are all part of the "pharmaceutical products" industry. VivoSim Labs vs. Its Competitors LAVA Therapeutics Alterity Therapeutics Xilio Therapeutics Jasper Therapeutics Pluri PyroGenesis Canada Senti Biosciences X4 Pharmaceuticals Dyadic International Mural Oncology LAVA Therapeutics (NASDAQ:LVTX) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings. Does the media refer more to LVTX or VIVS? In the previous week, LAVA Therapeutics had 6 more articles in the media than VivoSim Labs. MarketBeat recorded 6 mentions for LAVA Therapeutics and 0 mentions for VivoSim Labs. VivoSim Labs' average media sentiment score of 0.00 beat LAVA Therapeutics' score of -2.00 indicating that VivoSim Labs is being referred to more favorably in the news media. Company Overall Sentiment LAVA Therapeutics Very Negative VivoSim Labs Neutral Do insiders & institutionals have more ownership in LVTX or VIVS? 8.2% of VivoSim Labs shares are held by institutional investors. 9.5% of LAVA Therapeutics shares are held by insiders. Comparatively, 3.7% of VivoSim Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, LVTX or VIVS? LAVA Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, VivoSim Labs has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Do analysts prefer LVTX or VIVS? LAVA Therapeutics currently has a consensus target price of $2.69, suggesting a potential upside of 80.81%. Given LAVA Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe LAVA Therapeutics is more favorable than VivoSim Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LAVA Therapeutics 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00VivoSim Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is LVTX or VIVS more profitable? LAVA Therapeutics has a net margin of 0.00% compared to VivoSim Labs' net margin of -1,396.48%. VivoSim Labs' return on equity of -32.95% beat LAVA Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LAVA TherapeuticsN/A -106.29% -38.24% VivoSim Labs -1,396.48%-32.95%-21.31% Which has preferable earnings & valuation, LVTX or VIVS? VivoSim Labs has lower revenue, but higher earnings than LAVA Therapeutics. LAVA Therapeutics is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLAVA Therapeutics$11.98M3.26-$25.11M-$1.05-1.41VivoSim Labs$140K77.07-$2.48M-$10.20-0.41 SummaryVivoSim Labs beats LAVA Therapeutics on 8 of the 15 factors compared between the two stocks. Get VivoSim Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for VIVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIVS vs. The Competition Export to ExcelMetricVivoSim LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.79M$3.14B$5.77B$10.45BDividend YieldN/A2.35%5.61%4.57%P/E Ratio-0.4120.9180.5026.82Price / Sales77.07262.05456.1891.97Price / CashN/A46.4637.6661.43Price / Book0.759.6015.756.39Net Income-$2.48M-$53.22M$3.30B$271.80M7 Day Performance-0.95%3.11%5.35%3.51%1 Month Performance109.60%6.23%7.28%9.58%1 Year PerformanceN/A11.02%80.79%28.53% VivoSim Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIVSVivoSim Labs0.2551 of 5 stars$4.15+5.6%N/AN/A$10.79M$140K-0.4120LVTXLAVA Therapeutics1.3498 of 5 stars$1.51-0.3%$2.69+78.4%-8.9%$39.59M$4.99M-1.4360Negative NewsInsider TradeATHEAlterity Therapeutics1.9239 of 5 stars$4.44-0.2%$12.00+170.3%+264.2%$39.38MN/A0.0010Gap DownXLOXilio Therapeutics1.8821 of 5 stars$0.76-1.0%$3.00+295.8%+0.1%$39.29M$6.34M-1.0070JSPRJasper Therapeutics3.0654 of 5 stars$2.39-1.6%$28.75+1,102.9%-89.5%$39MN/A-0.4020News CoverageGap DownPLURPluri2.262 of 5 stars$4.90+0.1%$12.00+145.1%-10.4%$38.52M$330K-0.89150Negative NewsEarnings ReportPYRGFPyroGenesis CanadaN/A$0.20+6.1%N/A-69.3%$38.41M$9.14M-3.4190Gap DownSNTISenti Biosciences2.5683 of 5 stars$1.40+0.7%$8.50+507.1%-57.1%$36.62M$2.56M-0.164News CoveragePositive NewsShort Interest ↓XFORX4 Pharmaceuticals4.2869 of 5 stars$3.20-0.3%$34.17+967.7%-85.1%$36.51M$2.56M-0.2280DYAIDyadic International2.7786 of 5 stars$1.03+3.9%$6.00+483.1%-14.4%$36.15M$3.49M-5.267MURAMural Oncology2.727 of 5 stars$2.08+0.2%$12.00+478.3%-38.5%$35.96MN/A-0.24119 Related Companies and Tools Related Companies LAVA Therapeutics Alternatives Alterity Therapeutics Alternatives Xilio Therapeutics Alternatives Jasper Therapeutics Alternatives Pluri Alternatives PyroGenesis Canada Alternatives Senti Biosciences Alternatives X4 Pharmaceuticals Alternatives Dyadic International Alternatives Mural Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIVS) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VivoSim Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VivoSim Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
